Zura Bio Ltd
corporate_fare Company Profile
Zura Bio Ltd (NASDAQ:ZURA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ZURA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ZURA spans 8-K, 10-Q, 10-K, 4.
Recent high-impact activity:
- Zura Bio's Phase 2 TibuSHIELD Misses Primary Endpoint; HS Program Discontinued
- Zura Bio Posts $25.8M Q3 Loss as Cash Drops to $187.7M
- Zura Bio Q3 2026: Cash Falls to $187.7M, Loss Widens to $76.4M; HS Data Due Q4
- Zura Bio Q2 2026: $205M Cash and Tibulizumab Phase 2 Readouts on Track
- Zura Bio Q2 2026: Cash Runway Through 2028, Tibulizumab Phase 2 Data in Q4
Financial Snapshot
Short Interest & Short Volume
1.79 days to coverFINRA reported short interest of 8,471,655 shares in ZURA as of the October 30, 2026 settlement, a 20.7% increase from the prior period — about 1.8 days to cover at its recent average daily volume. On November 20, 2026, 31.5% of ZURA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ZURA, detected from its recent SEC filings · based on capital-structure filings through 2026-06-18.
Equity Incentive Plan Approved · Significant Share Authorization
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →